Literature DB >> 16219062

Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue?

Adel Afifi1, Hesham El-Sayed, Maged El-Setouhi, Hayam Ahmed, Noha Khalifa.   

Abstract

The prevalence of hyperphosphatemia and increased calcium-phosphorus product has never been evaluated in a large multicenter study in a developing country. Our aim is to study the prevalence of hyperphosphatemia in 38 HD centers in Egypt (as an example of a developing country) and to correlate it with different co-morbid conditions and the patient's demographic data. This is a cross-sectional study conducted on 1005 chronic kidney disease stage 5 patients (CKD-stage 5) on HD for a period of more than 1 year in 38 dialysis centers in Egypt. All patients were receiving calcium-based salts as a phosphate binder. Hyperphosphatemia and increased calcium-phosphorus product were evaluated and correlated with different parameters including age, sex, knowledge by diet parameters, HD session duration, the frequency of HD per week, the type of dialysis membrane, the surface area of the dialyzer, dialyzer phosphorus clearance (phosphorus KoA), and the type of dialysate. Other co-morbid medical conditions and evidence of IHD were also investigated. Hyperphosphatemia was present in 69.1% of cases and a high calcium-phosphorus product was present in 30.2%. A higher calcium-phosphorus product was found among males. 83.2% of those with a poor knowledge by diet parameters had hyperphosphatemia compared with 67.6% in patients with a satisfactory knowledge by diet parameters. 72.3% of patients using a membrane with low-to-medium clearance had hyperphosphatemia, compared with 67.2% using a membrane with a high clearance. Seventy-two percent of patients with IHD were hyperphosphatemic compared with 67.6% of the non-ischemic patients. Hyperphosphatemia is a major problem in dialysis patients in developing countries, reflecting differences from developed countries regarding dietary habits, ethnic factors, dialysis quality, types of dialysis membranes, as well as economic factors hampering the use of the more expensive phosphate binders. Extended dialysis hours may be a good alternative solution in developing countries.

Entities:  

Mesh:

Year:  2005        PMID: 16219062     DOI: 10.1111/j.1542-4758.2005.01160.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  5 in total

1.  Patient Knowledge, Adherence to the Therapeutic Regimen, and Quality of Life in Hemodialysis : Knowledge, Adherence, and Quality of Life in Hemodialysis.

Authors:  Victoria Alikari; Vasiliki Matziou; Maria Tsironi; Paraskevi Theofilou; Natalia Giannakopoulou; Foteini Tzavella; Evangelos C Fradelos; Sofia Zyga
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis.

Authors:  Yong Wang; Guoqiang Xie; Yuanhang Huang; Han Zhang; Bo Yang; Zhiguo Mao
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

3.  Low calcium dialysate combined with CaCO3 in hyperphosphatemia in hemodialysis patients.

Authors:  Zhuo Gao; Li-DE Lun; Xin-Lun Li
Journal:  Exp Ther Med       Date:  2013-04-17       Impact factor: 2.447

4.  Use of Phosphate Binders in End-Stage Renal Disease: An Experience From a Secondary Care Hospital in United Arab Emirates.

Authors:  Syed Arman Rabbani; Sathvik B Sridhar; Padma G M Rao; Martin T Kurian; Basset E Essawy
Journal:  J Pharm Bioallied Sci       Date:  2019 Apr-Jun

5.  Prevalence of Renal Osteodystrophy and its Related Factors among End-stage Renal Disease Patients Undergoing Hemodialysis: Report from Imam Reza Referral Hospital of Medical University of Kermanshah, Iran.

Authors:  Abolhassan Seyedzadeh; Mohamad Reza Tohidi; Sima Golmohamadi; Hamid Reza Omrani; Mohammad Saleh Seyedzadeh; Sara Amiri; Sara Hookari
Journal:  Oman Med J       Date:  2022-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.